Proteases that degrade the biofilm matrix
Keywords:bacterial biofilms, dispersion, extracellular bacterial proteases
Biofilms protect bacteria from the action of antibacterial drugs and are one of the mechanisms of antibiotic resistance of infections. Destruction of the bacterial biofilm matrix leads to the release of bacteria and they again become vulnerable to antibacterial agents. Various enzymes are involved in the degradation of various components of the excellular matrix of biofilms: proteases, glycosidases, deoxyribonucleases, which are secreted by bacteria and macroorganism cells. Numerous bacterial proteases and proteases of animal origin contribute to the dispersion of biofilms. Proteases are divided into two main groups: exo- and endopeptidases. Exopeptidases are involved in the dispersion of biofilms. Bacterial proteases perform two main functions: firstly, they are involved in providing the microorganism with peptide nutrients and, secondly, they contribute to the development of the infectious process. Bacteria of each family produce several proteases, the activity of which is directed against various targeted molecules. Bacterial proteases such as aureolysin, staphopaines A and B, streptococcal cysteine protease, V8 serine protease, Spl protease, lysostaphin, LasВ protease, LapG protease, serratiopeptidase, proteinase K, subtilisin and subtilisin-like enzymes that are involved in the breakdown of the bioprotein matrix contribute to the release of pathogenic bacteria, which leads to an increase in the effectiveness of antibiotic therapy and reduces the risk of an adverse course of severe bacterial infections. It has now been shown that the use of recombinant forms of lysostaphin, serratiopeptidase, proteinase K is accompanied by a decrease in the weight of the biofilm or its complete degradation and contributes to the sanogenesis of infectious diseases. Despite the fact that most of the identified proteases with antibiotic activity are currently in the phase of experimental study, there is no doubt that drugs developed on their basis will become drugs that will be used in the treatment of diseases caused by antibiotic-resistant infections.
Abtahi H, Farhangnia L, Ghaznavi-Rad E. In Vitro and in Vivo Antistaphylococcal Activity Determination of the New Recombinant Lysostaphin Protein. Jundishapur J Microbiol. 2016;9(3):e28489. doi:10.5812/jjm.28489.
Berscheid A, François P, Strittmatter A, et al. Generation of a vancomycin-intermediate Staphylococcus aureus (VISA) strain by two amino acid exchanges in VraS. J Antimicrob Chemother. 2014;69(12):3190–3198. doi:10.1093/jac/dku297.
Boksha IS, Lavrova NV, Grishin AV, et al. Staphylococcus simulans Recombinant Lysostaphin: Production, Purification, and Determination of Antistaphylococcal Activity. Biochemistry (Mosc). 2016;81(5):502–510. doi:10.1134/S0006297916050072.
Ceotto-Vigoder H, Marques SL, Santos IN, et al. Nisin and lysostaphin activity against preformed biofilm of Staphylococcus aureus involved in bovine mastitis. J Appl Microbiol. 2016;121(1):101–114. doi:10.1111/jam.13136.
Cherny KE, Sauer K. Untethering and Degradation of the Polysaccharide Matrix Are Essential Steps in the Dispersion Response of Pseudomonas aeruginosa Biofilms. J Bacteriol. 2020;202(3):e00575-19. doi:10.1128/JB.00575-19.
Coughlan LM, Cotter PD, Hill C, Alvarez-Ordóñez A. New Weapons to Fight Old Enemies: Novel Strategies for the (Bio)control of Bacterial Biofilms in the Food Industry. Front Microbiol. 2016;7:1641. doi:10.3389/fmicb.2016.01641.
Duman ZE, Ünlü A, Çakar MM, Ünal H, Binay B. Enhanced production of recombinant Staphylococcus simulans lysostaphin using medium engineering. Prep Biochem Biotechnol. 2019;49(5):521–528. doi:10.1080/10826068.2019.1599393.
Hogan S, Zapotoczna M, Stevens NT, Humphreys H, O'Gara JP, O'Neill E. Potential use of targeted enzymatic agents in the treatment of Staphylococcus aureus biofilm-related infections. J Hosp Infect. 2017;96(2):177–182. doi:10.1016/j.jhin.2017.02.008.
Kokai-Kun JF, Chanturiya T, Mond JJ. Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice. J Antimicrob Chemother. 2009;64(1):94–100. doi:10.1093/jac/dkp145.
Loughran AJ, Atwood DN, Anthony AC, et al. Impact of individual extracellular proteases on Staphylococcus aureus biofilm formation in diverse clinical isolates and their isogenic sarA mutants. Microbiologyopen. 2014;3(6):897–909. doi:10.1002/mbo3.214.
Martínez-García S, Rodríguez-Martínez S, Cancino-Diaz ME, Cancino-Diaz JC. Extracellular proteases of Staphylococcus epidermidis: roles as virulence factors and their participation in biofilm. APMIS. 2018;126(3):177–185. doi:10.1111/apm.12805.
Oscarsson J, Tegmark-Wisell K, Arvidson S. Coordinated and differential control of aureolysin (aur) and serine protease (sspA) transcription in Staphylococcus aureus by sarA, rot and agr (RNAIII). Int J Med Microbiol. 2006;296(6):365–380. doi:10.1016/j.ijmm.2006.02.019.
Pietrocola G, Nobile G, Rindi S, Speziale P. Staphylococcus aureus Manipulates Innate Immunity through Own and Host-Expressed Proteases. Front Cell Infect Microbiol. 2017;7:166. doi:10.3389/fcimb.2017.00166.
Roy R, Tiwari M, Donelli G, Tiwari V. Strategies for combating bacterial biofilms: A focus on anti-biofilm agents and their mechanisms of action. Virulence. 2018;9(1):522–554. doi:10.1080/21505594.2017.1313372.
Rybtke M, Berthelsen J, Yang L, Høiby N, Givskov M, Tolker-Nielsen T. The LapG protein plays a role in Pseudomonas aeruginosa biofilm formation by controlling the presence of the CdrA adhesin on the cell surface. Microbiologyopen. 2015;4(6):917–930. doi:10.1002/mbo3.301.
Selan L, Papa R, Tilotta M, et al. Serratiopeptidase: a well-known metalloprotease with a new non-proteolytic activity against S. aureus biofilm. BMC Microbiol. 2015;15:207. doi:10.1186/s12866-015-0548-8.
Tossavainen H, Raulinaitis V, Kauppinen L, Pentikäinen U, Maaheimo H, Permi P. Structural and Functional Insights Into Lysostaphin-Substrate Interaction. Front Mol Biosci. 2018;5:60. doi:10.3389/fmolb.2018.00060.
How to Cite
Copyright (c) 2020 А.Е. Abaturov
This work is licensed under a Creative Commons Attribution 4.0 International License.